Author:
Chen C.,Wood J.G.,Beutels P.,Menzies R.,MacIntyre C.R.,Dirmesropian S.,Reyes J.F.,McIntyre P.,Newall A.T.
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine
Reference30 articles.
1. Cost-effectiveness of vaccinating immunocompetent ≥65 Year Olds with the 13-valent pneumococcal conjugate vaccine in england;van Hoek;PLoS ONE,2016
2. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the united states;Stoecker;J. General Internal Med,2016
3. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands;Mangen;Europ. Respirat. J.,2015
4. The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: an exploration of influential factors for Belgium;Blommaert;Vaccine,2016
5. Blommaert, A. et al. Use of pneumococcal vaccines in the elderly: an economic evaluation. [Health Technology Assessment (HTA)] 2016 10/2016; Available from: https://kce.fgov.be/sites/default/files/page_documents/KCE_274_Pneumococcal_Report.pdf.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献